| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| VASCONCELLES MICHAEL | Head of Research and Dev. | C/O DAY ONE BIOPHARMACEUTICALS, INC., 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE | /s/ Charles N. York II, as Attorney-in-Fact | 18 Jun 2025 | 0001734755 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DAWN | Stock Option (right to buy Common Stock) | Award | $0 | +346,000 | $0.000000 | 346,000 | 16 Jun 2025 | Common Stock | 346,000 | $6.64 | Direct | F1 | |
| transaction | DAWN | Restricted Stock Unit (RSU) | Award | $0 | +226,000 | $0.000000 | 226,000 | 16 Jun 2025 | Common Stock | 226,000 | $0.000000 | Direct | F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | The option vests as to 1/4th of the total grant on June 16, 2026, and 1/48th of the total grant will vest on each monthly anniversary thereafter, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. |
| F2 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. |
| F3 | The RSUs vest as to 25% of the total award on August 15, 2026, and 1/12th of the remaining RSUs vest in quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each RSU vesting date. |
| F4 | RSUs do not expire; they either vest or are canceled prior to the RSU vesting date.. |